|

STX-721/PFL-721 (3 dose levels) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Pierre Fabre Medicament1

Indications

  • EGFR/HER2 Exon 20 Insertion Mutation1
  • NSCLC1
  • Lung Cancer1
  • Non Small Cell Lung Cancer1
  • Cancer1

Duarte, California1 trial

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

City of Hope

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.